Neurology | Neuro Oncology | Neuro Oncology Conference | Neurology Conference |Brisbane |Australia | USA | Asia

Theme: New Challenges and Latest Developments in Understanding Neuro-oncology and treating brain tumour

Neuro Oncology 2016

Neurooncology

Neuro Oncology 2016

We are happy to welcome you to the upcoming International Conference on Neuro-oncology and Brain Tumour, held during July 21-22, 2016, at Brisbane, Australia.

In Australia Every year about 2000 people are affected with brain and spinal cord tumors including children. Every year about 1,400 malignant brain Tumors are diagnosed in Australia out of which about 100 of these cases in Children and About 80 people are diagnosed with other Malignant Central nervous system tumors, including malignant and spinal tumors, about in five of these are children. Patients diagnosed with glioblastoma, the most aggressive form of glioma, their prognosis remains poor with the majority of patients dying from the disease within the two years of diagnosis.

This activity has been approved for AMA PRA Category 1 Credit™

PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live format for this educational activity for AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Track 1: Neuro-oncology

The nervous system is denounced to various malevolent disorders. Central Nervous System covers its mechanism, ramification, Metastatic pestilence, Cancers, Neurons and Sensory Receptors, Neurological Disorders, Neurodegenerative disease and Imaging agents to CNS neurofibroma.

Global Central Nervous System Drugs market to grow at a CAGR of -3.2% over the period 2011-2015. The global central nervous system (CNS) therapeutics peddle has been forecast to reach US$133 billion by the year 2018, which increases in disease ubiquity rates due to increase in population, introduction of new drugs, and increased outgo on healthcare

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th International conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency Association, Acoustic Neuroma Association and ADA Disability and Business Technical Assistance Program, Aicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development Institute, Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

Track 2: Brain Cancer

Brain Cancer agora is segregate on the basis of diagnosis and therapeutics. A brain cancer involves the growth of idiosyncratic cells in the tissues of the brain. Cardinal brain cancer involves malignant tumor, Brain stem tumors, germ cell fibro adenoma, pituitary adenomas, Tumor development, DIPG, Cellular biology of brain cancer, primary CNS lymphomas, Pathophysiology and peril aspect of brain cancer and prognosis of brain tumors.

In 2011, 1,724 brain cancers were diagnosed in Australia. The risk of being pronounced with a brain cancer by age 85 is 1 in 96 for men and 1 in 149 for women. In 2012, there were 1241 deaths in Australia effectuate by brain cancer.

The brain prognosis and tumour diagnosis regulates the market analysis of brain cancer

Key market players which make a part in this bailiwick are Antisense Pharma, Novartis AG, AstraZeneca, Bristol-Myers Squibb, Pfizer Inc., Hoffmann-La Roche Ltd, Genentech and others.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Alzheimer's Association and Alzheimer's Foundation of America, American Association on Health and Disability and American Autoimmune Related Diseases Association, American Behcet's Disease Association and American Brain Coalition, American Brain Tumor Association and American Cancer Society, American Chronic Pain Association and American Diabetes Association.

Track 3: Glioblastoma

Glioblastoma multiforme (GBM) (specified as glioblastoma) is a presumptuous glioma which is developed from star-shaped glial units (i.e. astrocytes and oligodendrocytes) that stiffener the health of the nerve cellules within the brain. Almost 1 in 5 sarcoma in the brain are glioblastoma.

Glioblastoma multiforme occur most often in adults between the ages of 45 and 70 years. This carcinoma represents about 15.4% of all primary brain tumors and about 60-75% of all astrocytomas. They increase in recurrence with age, and affect more men than women. Only three per cent of childhood brain tumors are glioblastoma

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , American Dystonia Society and American Fibromyalgia Syndrome Association, American Headache Society Committee for Headache Education and American Heart Association, American Liver Foundation and American Parkinson Disease Association, American RSDHope Organization and American Sleep Apnea Association, American Speech-Language-Hearing Association and American Stroke Association: A Division of American Heart Association.

Track 4: Metastatic Cancer

When cancer develops everywhere in the body and escalation (metastasizes) to the brain, which is called as secondary brain tumefaction, or metastatic brain cancer. Brain metastases (secondary brain tumors) occur in approximately 15% of cancer patients as a result of haematogenous proclamation, of cancer, and the incidence may be rising because of better control of integral disease.

The overall annual incidence of principal brain tumors in the United States is 9.5 cases per 100,000 populations. Over 60% of primary brain carcinoma are gliomas, and at least two-thirds of these are clinically aggressive and high category. Brain tumors represent 20% of all childhood malignancies and are the number two cause of cancer death in children after leukaemia

American Syringomyelia and Chiari Alliance Project& amfAR, The Foundation for AIDS Research, Angelman Syndrome Foundation and Angioma Alliance, Antiepileptic Drug Pregnancy Registry and Aphasia Hope Foundation, Ara Parseghian Medical Research Foundation and Arc of the United States, Arthritis Foundation and Association for Frontotemporal Degeneration

Track 5: Angiogenesis in Neuro-Oncology

Angiogenesis theatrically a critical role in the maturation and spread of cancer, it also plays a major role in the transition of tumor cells from a benign state to a malignant (cancerous), leading to the use of angiogenesis evasion in the treatment of cancer.

Angiogenesis is a vital series that facilitates tumor growth and survival. Angiogenesis is a well-controlled path that is systematize by angiogenic, growth, and survival factors that are secreted by the malignant units as well as other corpuscle within the tumor microenvironment

Track 6: Radiation Oncology

Radiation Oncology encompasses all facet, of research that whack, on the treatment of cancer using radiation. It discloses verdict in molecular and cellular radiation oncology, radiation technology, radiation physics, and clinical oncology.

Radiation Oncology is fabricated up of three unique medical specialties that focus on the treatment of cancer patients with radiotherapy treatment (also known as radiation therapy); videlicet Radiation Oncologists, Radiation Therapists and Radiation Physicists.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Society for Neuroscience 2016 Annual Meeting ,Association for Glycogen Storage Disease and Association for Science in Autism Treatment, A-T Ease Foundation, Inc. and Ataxia Telangiectasia , Attention Deficit Disorder Association and Autism National Committee , Autism Network International and Autism Research Institute , Autism Science Foundation and Autism Society of America.

Track 7: Diagnosis of Neuro-Oncology

The primary method which is used in the initial diagnosis, monitoring of response, and process of progression in Neuro-oncology is neuroimaging techniques. Neuro imaging has enabled great progress in the diagnosis of brain cancer, as well as finding useful application in medical research and practice.

There are a number of accepted, safe imaging techniques in use today in research facilities and hospitals throughout the world which includes FMRI, CT scan, PET, EEG, MEG, and NIRS. This session includes latest technologies and developments of Structural and functional imaging, Biomarker Discovery, Radioactive compounds in Neuroimaging, Computed tomography, Diffuse optical imaging, Magnetic resonance imaging, Positron emission tomography.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology,Association for Glycogen Storage Disease and Association for Science in Autism Treatment, A-T Ease Foundation, Inc. and Ataxia Telangiectasia , Attention Deficit Disorder Association and Autism National Committee , Autism Network International and Autism Research Institute , Autism Science Foundation and Autism Society of America.

Track 8: Pain Management in Neuro-Oncology

About one-third of patients are being analysed for cancer pain, which leads to many different forms. It may be short-lived or long-lasting, lenient or severe, or concomitant on few organs, bones or organ system. Since each patient’s pain is solitary, it is persuade that cancer pain management treatment plans must be adapt to address individual needs.

A market discernment, company based in the U.S, states that the Global pain management devices market was estimated at US$2.0 billion in 2011 and, estimated to pullulate, at a CAGR of 13.1% from 2011 to 2018, is predicted to reach the value of US$5.0 billion by 2018.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis& Acid Maltase Deficiency Association, Acoustic Neuroma Association and ADA Disability and Business Technical Assistance Program, Aicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development Institute, Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

Track 9: Pediatric Neuro-oncology

Pediatric Neuro-oncology is a sparkly developing field. Brain tumors are the fountainhead of cancer-related deaths aimed children. Brain disorders are the most common solid malignancy in children. Their bodies and brains are still developing, their tumors are different. The communal, childhood brain cancers are not the same as the most common adult brain cancers. Though they are sparse, brain tumors are very common form of solid tumors among children under the age of 15 and illustrate, about 20% of all childhood cancers.

Childhood tumors frequently appear in different locations and behave contradictory than brain tumors appearing in adults. Treatment options are different and can be vigorous pressurize by the age of the child. Children suffering from brain cancer may also occupy a much better prognosis than adults with a similar zone. The regular types of brain tumors in infants and children are Neurofibromatosis, Primitive Neuroectodermal tumor, Blood Cancer, Neuroblastoma, Medulloblastoma, Ependymoma and Astrocytoma.

Survival range for brain tumors vary widely superlatively on the type of tumor and other factors, including age. Five-year survival rates range from 66% for toddler; ages 0 - 19 years to 5% for adults age 75 years and older. Advancements in treatment have dramatically

multiply survival rates for children with brain tumors. About 75% of children survive at least 5 years after being pronounced with a brain tumor. Brain cancers account for about 15% of pediatric cancers and are the second most common vintage of cancer in children. The specific treatment and prognosis depends on the grade, type, and location of the tumor. Depending on the genre of tumor and the timeliness of pronouncement , the 5 year survival growth rate is 40-80%.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Alzheimer's Association and Alzheimer's Foundation of America, American Association on Health& Disability and American Autoimmune Related Diseases Association, American Behcet's Disease Association and American Brain Coalition, American Brain Tumor Association and American Cancer Society, American Chronic Pain Association and American Diabetes Association.

Track 10: Neurosurgery

Neurosurgery is a complex surgical method that presupposes treatment, diagnosis, and rehabilitation of disorders affecting any region of the nervous system.

Some of the preponderance common Neuro surgeries are skull base surgery, Image Guided Surgery, Laser Surgery , spinal Neurosurgery and Neuro surgical treatment. The Global Neurosurgery market is expected to raise 11.71% over the session of 2014-2019.

Neurosurgery session includes Image Guided Surgery, Laser Surgery, Surgical operation for brain fibro adenoma, spinal neurosurgery, skull base surgery, Neuro surgical treatment, Geriatric Neurosurgery, latest innovations and techniques.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , American Dystonia Society and American Fibromyalgia Syndrome Association, American Headache Society Committee for Headache Education and American Heart Association, American Liver Foundation and American Parkinson Disease Association, American RSDHope Organization and American Sleep Apnea Association, American Speech-Language-Hearing Association and American Stroke Association: A Division of American Heart Association.

Track 11: Neuropathology

Neuropathology is the dissertation of contagion of nervous system tissue, usually in the form of either small surgical biopsies or whole autopsies. Neuropathology is a sub long-suit of anatomic pathology, neurology, and neurosurgery.

Work of the neuropathologist consists predominantly, of largely of examining biopsy tissue from the brain and spinal cord to aid in interpretation of disease. The biopsy is usually requested after a mass is detected by radiologic imaging. As for autopsies, the principal drudgery, of the neuropathologist is to help in the post-mortem diagnosis of various forms of dementia and other affliction that affect the central affect the central nervous system.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , American Syringomyelia and Chiari Alliance Project and amfAR, The Foundation for AIDS Research, Angelman Syndrome Foundation and Angioma Alliance, Antiepileptic Drug Pregnancy Registry and Aphasia Hope Foundation, Ara Parseghian Medical Research Foundation and Arc of the United States, Arthritis Foundation and Association for Frontotemporal Degeneration

Track 12: Tumour Heterogeneity

Metastasis heterogeneity establish differences betwixt tumours of the same type in different patients, and also altercation between malignancy cells within a tumour cells can show distinct including cellular morphology, motility, gene idiom,, proliferation, metabolism, and metastatic potential. This process occurs both between tumours which is called as inter-tumour heterogeneity and confines of tumours called as intra-tumour heterogeneity. It plays a major role in brain Metastasis.

Genetic and epigenetic incongruity, between cancer cells within a tumour might explain why some tumour cells abiding present in the patient even after cancer treatment has finished. Most current efforts are focused on understanding hetero-topic interactions allying tumor cells and surrounding normal cells, which is known about the interactions between and among heterogeneous tumor cells within a neoplasm. Metastasis Heterogeneity covers Inter- intra tumour heterogeneity, Cancer Stem Cells, Brain Tumor Micro-environment, Experimental- Sequencing, Genetic Heterogeneity and Implications and challenges.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Association for Glycogen Storage Disease and Association for Science in Autism Treatment, A-T Ease Foundation, Inc. and Ataxia Telangiectasia , Attention Deficit Disorder Association and Autism National Committee , Autism Network International and Autism Research Institute , Autism Science Foundation and Autism Society of America.

Track 13: Therapeutic Approaches

Brain malignancy market is segmented on the essence of diagnosis and therapeutics. Major research is going on targeted Therapies for Brain malignancy. On the basis of treatment the market is segmented into surgeries, radiation therapy, immunotherapy, chemotherapy and targeted analysis. Therapeutic approaches include Chemical therapy Intensity modulated radiation therapy, palliative custody, vaccine therapy, surgical delivery, Molecular pathology for clinician and challenges in analysis.

Global cancer drugs and treatments agora will reach $143.7 billion by 2023. The Anti-cancer treatment market is already worth $77.4 billion (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency Association, Acoustic Neuroma Association and ADA Disability and Business Technical Assistance Program, Aicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development Institute, Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

Track 14: Case Studies in Neuro-Oncology

Brain Cancer clinical trials are research studies that test new and better ways to prevent, diagnose and treat Brain cancer. A world-first human trial has been set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer, researchers say. According to the Cure Brain Cancer Foundation worth of $500,000 provided to the study over the next three years.

The Centre for Neuro-Oncology offers the latest advances in care for adult patients with brain tumors or spinal cord tumors, as well as for neurologic complications of brain cancer and its treatments. The Australian Government is supporting Australia’s capacity to develop industry-independent cancer clinical trials.

6^th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2^nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2^nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7^th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1^st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6^th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17^th international conference on pediatric neurooncology , Alzheimer's Association and Alzheimer's Foundation of America, American Association on Health and Disability and American Autoimmune Related Diseases Association, American Behcet's Disease Association and American Brain Coalition, American Brain Tumor Association and American Cancer Society, American Chronic Pain Association and American Diabetes Association.

We are happy to welcome you for the official website of International Conference on Neuro-oncology and Brain tumour during July 21-22, 2016 at Brisbane, Australia with the theme of New Challenges and Latest Developments in Understanding and Treatment of Neuro-oncology.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and Conference Series, LLC. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

Overview of Neuro-oncology and Brain tumour:

Quality of life is an important area of clinical Neuro-oncology and Brain tumour that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies. Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiform, and high-grade (highly anaplastic) astrocytoma are among the worst.

Geographically market is segmented into Europe, North America, Latin America, Asia pacific, and Middle East and Africa. According to market study, Market Value for Neuro Oncology (i.e on Brain Cancer and CNS Tumors) will be more than double to $ 623 Million by 2020. A major part of research is going on the top Universities on across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.

Why to attend?

International Conference on Neuro Oncology to bring together worldwide distinguished academics in the field of Neuro-oncologist, Oncologist, Radiation Oncologist, Medical Oncologists, Neuropharmacology, Neurology, Neuropediatricians, Pediatric Oncologists, Neurosurgeons, Neurophysiologists, Neuroscience Brain researchers, Public Health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. Attending International conference is for the Professional Development and to understand the current state of research and the challenges to future discovery

The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.

Target Audience

Directors, Head of Department, Professors, Industrial Researchers, Neuro-oncologist, Radiation Oncologists, Oncologists, Neuropediatricians, Neurophysiologists, Neurosurgeons, Neurologist, Neuroradiologist, Neuro-Pathologists, Rehabilitation Specialists , Nurses, Neuroscience Researchers and Students from academia in the research of Neuro-oncology.Neurooncology Associations,Brain tumour societies

Target Audience:

Academia: 65%

Industry: 25%

Others: 10%

About the conference:

OMIC International is organising an International Conference on “Neuro-oncology and Brain tumour” during July 21-22, 2016 at Australia. The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology. The Conference will help the Scholars to produce publishable quality of research papers.

OMICS International is one of the leading organisation in conducting worldwide conferences which organizes 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums on various topics of Science & Technology across the globe with support from 1000 more scientific societies and Publishes 500+ Open Access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Overview of Neuro-oncology and Brain tumour:

Quality of life is an important area of clinical Neuro oncology that is increasingly relevant as survivorship increases and as patients experience potential morbidities associated with new therapies.Neurooncology associations and brain cancer societies take part of it.Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are (at least eventually) very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiform, and high-grade (highly anaplastic) astrocytoma are among the worst.

Importance and Scope:

Neuro-oncology and Brain tumour 2016 aims to faster the advancement of scientific knowledge that may ultimately result in a better prognosis for patients. International conference which is the Best platform to develop new partnership & collaborations .It provides an important base for the exchange of knowledge and experience amongst the clinicians and researchers involved in brain tumour research and patient management. The internationally renowned speakers at this conference will explore the clinical aspects of current Neuro-oncology research, quality of life issues and comprehensive patient care that takes into account the patient’s needs.

Why to attend?

International Conference on Neuro Oncology to bring together worldwide distinguished academics in the field of Neuro oncologist , Oncologist, Radiation Oncologist, Medical Oncologists Neuropediatricians, Neurophysiologists, Neuropsychiatrists , Neuroscience and Neurology, Brain researchers, Public Health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. Attending International conference is for the Professional Development and to understand the current state of research and the challenges to future discovery.

Market Analysis:

Geographically market is segmented into North America, Europe, Asia pacific, Latin America and Middle East and Africa. According to market study, Market Value for Neuro Oncology Will More than Double to $623 Million by 2020. A major part of research is going on the top Universities on Neuro Oncology across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.

Why Australia?

Malignant brain tumors and other central nervous system cancers represent highly challenging and devastating group of cancers. While the incidence of brain cancer is relatively low, mortality is high with the most recently reported 5-year survival rates at ~19–35% in Australia, United Kingdom, and America. The population of 23.6 million is highly urbanised and heavily concentrated in the eastern states and on the coast.

In Australia Every year about 2000 people are effected with brain and spinal cord tumors including children. Every year about 1,400 malignant brain Tumors are diagnosed in Australia. About 100 of these cases in Children. About 80 people are diagnosed with other Malignant Central nervous system tumors, including malignant and spinal tumors, about in five of these are children. Patients diagnosed with glioblastoma, the most aggressive form of glioma, their prognosis remains poor with the majority of patients dying from the disease within the two years of diagnosis.

Effect of Neuro Oncology across the Globe:

The incidence rate of all primary malignant and non-malignant brain and CNS tumors is 21.42 cases per 100,000 for a total count of 343,175 incident tumors; (7.25 per 100,000 for malignant tumors for a total count of 115,799 incident tumors and 14.17 per 100,000 for non-malignant tumors for a total count of 227,376 incident tumors). The rate is higher in females (23.26 per 100,000 for a total count of 198,212 incident tumors) than in males (19.42 per 100,000 for a total count of 144,963 incident tumors).

Major Associations of Neuro Oncology Worldwide:

Asian Society for Neuro-Oncology

Australian Oncology Social Work Inc.

SNO Society for Neuro Oncology

American Society of Clinical Oncology

American Brain Tumor Association

American Cancer Society

European Scientific Society

Canadian Cancer Society

National Brain Tumor Society

Major Associations of Neuro Oncology in Australia:

Cooperative Trials Group for Neuro-Oncology(COGNO)

Australian Oncology Social Work Inc.

The Sydney Neuro-Oncology Group

The Cancer Institute of NSW

Brain Foundation National and New South Wales

Cure for Life Foundation

Brain Link Services Ltd(Melbourne)

The Cancer Council Victoria:

Centre for Minimally Invasive Neurosurgery

Ahepa medical foundation

Bowerhaus

Athanase yenibis foundation

The Victorian Brain and Spine Centre (VBSC)

Centre for Minimally Invasive Neurosurgery

Clinical Oncological Society of Australia [COSA]

Australian Pituitary Foundation Ltd

Clinical Oncological Society of Australia [COSA]

Occupational Therapy Australia.

Red kite

Starlight

Make a Wish

Medical Oncology Group of Australia

Brain Tumour Alliance Australia.

Oz Brain Tumour

Adult Brain Cancer Support Association,

Brain Tumour Association Western Australia

James Crofts Hope Foundation

National Cancer Cooperative Trials Groups

The Australian Government is supporting Australia’s capacity to develop industry-independent cancer clinical trials. The following National Cancer Cooperative Trials Groups are currently funded by Cancer Australia:

Australia and New Zealand Melanoma Trials Group

Australian and New Zealand Children’s Haematology and Oncology Group

Australasian Sarcoma Study Group

Cooperative Trials Group for Neuro-Oncology

Primary Care Collaborative Cancer Clinical Trials Group

Psycho-Oncology Co-operative Research Group

Trans-Tasman Radiation Oncology Group

Funds Providing Organisations:

American Brain Tumor Association (ABTA)

ACT Brain Tumor

Ben and Catherine Ivy Foundation

Brain Tumor Foundation of Canada (BTFC)

Brain Tumor Funder's Collaborative

Childhood Brain Tumor Foundation

Concern Foundation

Congressionally Directed Medical Research Programs

Gold Hirsh Foundation

Grey Ribbon Crusade

Matthew Larson Foundation

National Brain Tumor Society

NBTS & AANS/CNS Section on Tumors

Pediatric Brain Tumor Foundation

Pediatric Oncology Grants

Sontag Foundation

Key Market Players across the Globe:

AstraZeneca

Antisense Pharma

EMD Serono Inc.

GlaxoSmithKline

Bristol-Myers Squibb

Pfizer Inc.

F. Hoffmann-La Roche Ltd

Novartis AG

Key Market Players in Australia:

Novogen Limited

Melbourne bio-pharmaceutical company

North Shore-LIJ

Recent advances on drug Development in Australia:

1)A world-first human trial set to begin in Brisbane and Melbourne has the potential to be one of the biggest breakthroughs in the treatment of brain cancer.

2)A new drug, Gliolan (aminolevulinic acid) is now being used in patients with glioblastoma multiforme (GBM) by some Australian neurosurgeons to improve intraoperative identification and visualisation of the margins between tumour and normal brain tissue. This in turn assists the surgeon to more completely remove the malignant tissue

Target Audience

Target Audience:

Academia: 65%

Industry: 25%

Others: 10%

A major part of research is going on the top Universities on Neuro Oncology across the globe like

Cern Medical Research

Stanford University in California

UC San Diego

University of Wolver Hampton

University of Chicago

University Hospital Heidelberg

University of Michigan Health System

Duke University in Durham, NC

Washington University in St. Louis, MO

University of California

Harvard Medical School

UCSF School of Medicine

Perelman School of Medicine

Yale School of Medicine

Maryland School of Medicine

Warren Alpert Medical School

University of Virginia.

University of Rochester Medical Centre

A major part of research is going on the top Universities on Neuro Oncology in Australia.

Macquarie University

University of New South Wales

University of Sydney

University of Newcastle

University of Western Sydney

University of New England

University of Melbourne

Victoria University

University of Queensland

University of Western Australia

Hospitals in Australia:

Radiation Oncology Victoria

Sydney Radiotherapy & Oncology Centre

Royal Brisbane & Women's Hospital

Macquarie Health Corporation

Queensland Fertility Group

The Royal Children's Hospital Melbourne

The Wesley Hospital (Brisbane, QLD)

Princess Alexandra Hospital (Brisbane, QLD)

The Mater Private (Brisbane, QLD)

Pindara Hospital (Gold Coast, QLD)

The Prince of Wales Hospital (Sydney, NSW)

Newcastle Private Hospital (NSW)

Wollongong (NSW)

Royal Melbourne Hospital (VIC)

Epworth Private Hospital (VIC)

St Vincent's Private Hospital (VIC)

Memorial Hospital (Adelaide, SA)

Calvary (Hobart, TAS)

Dunedin (NZ)

Wellington (NZ)

Waikato (NZ)

Hospitals in Worldwide:

Leiden University Medical Centre

Royal Cancer Hospital

King’s College Hospital

Clatterbridge Centre for Oncology

Northampton General Hospital

Cambridge University Hospitals

University Hospital Southampton

Central Manchester University Hospitals

South end University Hospital

Kingston Hospitals

Bradford Hospital

Institute of Oncology, Ljubljana

Institute Gustave Roussy, Paris

Paterson Institute On Cancer Research,UK

Christie Hospitals

Wellington Hospital

Imperial College Hospital

Curie Institute

Cleveland clinic

List of cancer drugs approved by the FDA for use in brain tumors

Gliolan

TRXE-009

Temozolomide

Afinitor (Everolimus)

Afinitor Disperz (Everolimus)

Avastin (Bevacizumab)

Becenum (Carmustine)

Bevacizumab

BiCNU (Carmustine)

Carmubris (Carmustine)

Carmustine

Carmustine Implant

CeeNu (Lomustine)

Everolimus

Gliadel (Carmustine Implant)

Gliadel wafer (Carmustine Implant)

Lomustine

Methazolastone (Temozolomide)

Temodar (Temozolomide)

Organisation	Type	Amount
Accelerate Brain Cancer Cure	Grants	Upto $250K
American Brain Tumor Association (ABTA)	Grants	$75,000
Ben and Catherine Ivy Foundation	Grants	Upto $3 Million
Brain Tumor Funder's Collaborative	Grants	up to $100,000
Childhood Brain Tumor Foundation	Grants	Up to $30,000
Concern Foundation	Grants	$60,000
Goldhirsh	Grants	$600,000
Goldhirsh	Research Rewards	$100,000
Grey Ribbon Crusade	Grants	up to $70,000
Matthew Larson Foundation	Grants	up to $75,000
James S. McDonnell	Grants	$450,000
John McNicholas Glioma Scholar Award	Grants	$200,000
National Brain Tumor Society	Grants	$300,000
NBTS & AANS/CNS Section on Tumors	Grants	$75000
Pediatric Brain Tumor Foundation	Grants	$2.5 Million
Sontag Foundation	Grants	$600,000

Dear Colleagues

As a member of the Organizing Committee it is my pleasure to invite you to attend Neuro-oncology and Brain tumour 2016 in Brisbane, Australia. The field of Neuro-Oncology is unlimited with the help of Associations of neurooncology and brain tumour Societies.since it also covers neurological complications of systemic cancers. Paraneoplastic Neurological Syndromes represent an intriguing model of interaction between the immune system and tumours and could make an interesting contribution to knowledge of the aetiopathogenesis of tumour development and neuroimmunological disorders.

The time is right to review the state of the art of PNS at both a clinical and immunopathological level.

We look forward to bringing new knowledge to the table in Brisbane.

Bruno Giometto

Vice President

Italian Society of Neurology

------------------------------------------------------------------------------------------------------------------------------------------

Dear Delegates,

As a member of the Organizing Committee of the International Conference on Neuro-oncology and Brain tumour (July 21-22,2016) at Brisbane, Australia, I am honored to welcome you to this important event.

Neuro-oncology and Brain tumour is a very complex field, where multi-disciplinarity is the leading word and it represents the only way to effectively tackle important and still unmet medical needs, such as treatment of brain tumors and management of treatment-related side effects. Innovative treatments, advances in neuro-imaging, improvement in the knowledge of cancer biology, palliative care and preclinical models will be among the main topics of the congress.

My field of research is focused on the side effect of chemotherapy on the peripheral nervous system, a small aspect of neuro-oncology. However, as a neurologist I am well aware of the relevance of the problems more broadly related to the diagnosis and care of brain tumor patients, and of the need of an intensive collaboration with neurosurgeons, radiotherapist, oncologist as well as other healthcare providers in order to optimize our efforts and to maximize their results.

This meeting is intended to allow you, irrespective to your personal expertise, to share opinions and to contact expert in all the multiple aspects of modern neuro-oncology. To this aim several tracks have been identified and the meeting program will be designed in order to facilitate contacts with the several opinion leaders who will guarantee the highest possible scientific level to each session or workshop.

I do really hope you will join us in Brisbane to bring us your knowledge and to learn more on the most up-to-date aspects of the different facets of Neuro-oncology.

With best regards

Guido Cavaletti

President, Italian Peripheral Nerve Society

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	July 21-22, 2016
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

International Conference on Neuro Oncology and Brain Tumor July 21-22, 2016 Brisbane, Australia

Recommended Global Neuroscience Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Neuro Oncology 2016

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues